PMAM
VYGR icon

Picton Mahoney Asset Management’s Voyager Therapeutics VYGR Stock Holding History

Picton Mahoney Asset Management’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-4,328
Closed -$15K – 1186
2025
Q1 		$15K Sell
4,328
-1,555
-26% -$7.26K ﹤0.01% 609
2024
Q4 		$33K Buy
5,883
+2,444
+71% +$15.8K ﹤0.01% 423
2024
Q3 		$20K Buy
3,439
+2,641
+331% +$19.2K ﹤0.01% 485
2024
Q2 		$6K Buy
+798
New +$6.69K ﹤0.01% 517

Other funds holding VYGR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Picton Mahoney Asset Management's VYGR Position: Q2 2025 in Review

Picton Mahoney Asset Management sold out of Voyager Therapeutics (VYGR) in Q2 2025, closing a stake of 4,328 shares — an estimated $15K sold.

Picton Mahoney Asset Management first reported a position in VYGR in Q2 2024 and held it in 4 quarters. The position peaked at $33K in Q4 2024. 112 funds tracked by Wall St. Rank hold VYGR as of Q2 2025.

  • Picton Mahoney Asset Management reported no remaining Voyager Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Picton Mahoney Asset Management sold 4,328 Voyager Therapeutics shares in Q2 2025, an estimated $15K.
  • Picton Mahoney Asset Management first reported a position in Voyager Therapeutics in Q2 2024 and held it in 4 quarters.
  • Picton Mahoney Asset Management's Voyager Therapeutics position peaked at $33K in Q4 2024.
  • 112 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2025.

Based on Picton Mahoney Asset Management's 13F filing for Q2 2025, filed 12 Aug 2025.